2020
DOI: 10.1016/j.jval.2020.03.021
|View full text |Cite
|
Sign up to set email alerts
|

Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018

Abstract: Objectives: Hepatitis C virus (HCV) antivirals have been shown to be highly effective with minimal adverse effects, but they are costly. Little is known about the national spending on this drug class in either Canada or the United States, 2 countries with different drug pricing regulations. Thus the objective of this study was to compare drug expenditure on HCV medications in the United States and Canada.Methods: This was a retrospective cross-sectional study using the IQVIA National Sales Perspectives (United… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
9
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9
1

Relationship

3
7

Authors

Journals

citations
Cited by 16 publications
(9 citation statements)
references
References 24 publications
0
9
0
Order By: Relevance
“…For example, in 2013, symptomatic dengue cases in 141 countries caused socio-economic costs of US$ 8.9 billion [4], while the costs of the latest Zika outbreak have been estimated to be US$ 7-18 billion in Latin America and the Caribbean from 2015 to 2017 [5]. Furthermore, between 2014 and 2018, the USA spent around US$ 60 billion on hepatitis C medication, with around US$ 80,000 per patient [6,7].…”
Section: Introductionmentioning
confidence: 99%
“…For example, in 2013, symptomatic dengue cases in 141 countries caused socio-economic costs of US$ 8.9 billion [4], while the costs of the latest Zika outbreak have been estimated to be US$ 7-18 billion in Latin America and the Caribbean from 2015 to 2017 [5]. Furthermore, between 2014 and 2018, the USA spent around US$ 60 billion on hepatitis C medication, with around US$ 80,000 per patient [6,7].…”
Section: Introductionmentioning
confidence: 99%
“…For example, in 2013, symptomatic dengue cases in 141 countries caused socioeconomic costs of US$ 8.9 billion [4], while the costs of the latest Zika outbreak has been estimated as US$ 7-18 billion in Latin America and the Caribbean from 2015 to 2017 [5]. Furthermore, between 2014 and 2018, the USA spend around US$ 60 billion for hepatitis C medication with around US$ 80,000 per patient [6,7]. Treatment options are limited for the majority of plus-strand RNA viruses.…”
Section: Introductionmentioning
confidence: 99%
“…Close to 71 million people are chronically infected with the hepatitis C virus (HCV) worldwide [ 1 ]. If left untreated, chronic HCV infection can cause substantial morbidity and mortality, with complications including cirrhosis, end-stage liver disease, and hepatocellular carcinoma [ 2 , 3 ]. Published models that assume absence of treatment suggest that cases of end stage liver disease among HCV-infected people will peak between 2030 and 2035 [ 4 ].…”
Section: Introductionmentioning
confidence: 99%